In a recent review article, written by clinical research scientists of NIZO and CR2O, potential health benefits of the best-documented probiotic strains to date, Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animals subspecies lactis (BB-12) were reviewed.
Health benefits of probiotics LGG and BB-12
Screening of more than 3000 articles resulted in 76 studies that met the selection criteria. Evidence showed that BB-12 and LGG supplementation may promote human health and support the daily wellness of consumers in important health domains. All papers reporting on clinical effects of BB-12 or LGG supplementation, or both, in healthy adults (or patient populations that are considered representative for effects in the general population) were included. There is evidence that BB-12 beneficially affects stool frequency in populations with reduced stool frequency. LGG appears to prevent Antibiotic-associated diarrhea (AAD) in patients treated for H. pylori infection. Both LGG and BB-12 (separately and in combination) are suggested to support immune defense against pathogens in the upper respiratory tract.
Scientific support of probiotic health claims needs strengthening
Criteria for the scientific substantiation of a health claim are very stringent, especially in Europe, and most (earlier) trials do not meet these stringent standards. Alwine Kardinaal, clinical research scientist at NIZO: “Probiotic innovation can be accelerated by well-designed, appropriately powered studies building on promising data, specifically in the areas mentioned above, where strong associations have been demonstrated.”
For more information, contact Alwine Kardinaal.